Maze Therapeutics (MAZE) Change in Accured Expenses (2024 - 2026)

Maze Therapeutics' Change in Accured Expenses history spans 3 years, with the latest figure at -$4.1 million for Q1 2026.

  • On a quarterly basis, Change in Accured Expenses fell 282.5% to -$4.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $479000.0, a 83.34% decrease, with the full-year FY2025 number at $3.5 million, down 8.54% from a year prior.
  • Change in Accured Expenses hit -$4.1 million in Q1 2026 for Maze Therapeutics, down from $2.0 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for MAZE hit a ceiling of $3.8 million in Q2 2024 and a floor of -$4.1 million in Q1 2026.
  • Historically, Change in Accured Expenses has averaged $358111.1 across 3 years, with a median of $106000.0 in 2025.
  • The widest YoY moves for Change in Accured Expenses: up 245.31% in 2025, down 711.45% in 2025.
  • Tracing MAZE's Change in Accured Expenses over 3 years: stood at $1.8 million in 2024, then rose by 6.51% to $2.0 million in 2025, then crashed by 307.13% to -$4.1 million in 2026.
  • Business Quant data shows Change in Accured Expenses for MAZE at -$4.1 million in Q1 2026, $2.0 million in Q4 2025, and $2.5 million in Q3 2025.